Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
October 11, 2006

Caprion Enters Oncology Target Licensing Agreement with Centocor

  • Caprion Pharmaceuticals will contribute protein targets to Centocor Research and Development for the development of Mabs and other therapeutic products for various cancer indications under a recent license agreement between the two companies.

    Caprion will select promising cancer targets using its CellCarta® proteomics technology platform. Centocor will have exclusive, worldwide rights to develop and commercialize therapeutics against any target it selects.

    The financial terms of the agreement include an upfront payment, license fees, milestone payments relating to the development of products by Centocor, and royalties on commercial sales of such products.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.